Abstract
Highlights In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m2 , dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.
Keywords:
2型糖尿病; body mass index; dulaglutide; type 2 diabetes; 体重指数; 杜拉鲁肽.
© 2020 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
MeSH terms
-
Adult
-
Biomarkers / blood
-
Blood Glucose / drug effects*
-
Blood Glucose / metabolism
-
Body Mass Index*
-
China
-
Clinical Trials, Phase III as Topic
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / diagnosis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Administration Schedule
-
Female
-
Glucagon-Like Peptide-1 Receptor / agonists
-
Glucagon-Like Peptides / adverse effects
-
Glucagon-Like Peptides / analogs & derivatives*
-
Glucagon-Like Peptides / therapeutic use
-
Glycemic Control* / adverse effects
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / adverse effects
-
Immunoglobulin Fc Fragments / adverse effects
-
Immunoglobulin Fc Fragments / therapeutic use*
-
Incretins / administration & dosage*
-
Incretins / adverse effects
-
Male
-
Middle Aged
-
Randomized Controlled Trials as Topic
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / therapeutic use*
-
Time Factors
-
Treatment Outcome
-
Weight Loss / drug effects
Substances
-
Biomarkers
-
Blood Glucose
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Immunoglobulin Fc Fragments
-
Incretins
-
Recombinant Fusion Proteins
-
Glucagon-Like Peptides
-
dulaglutide